Belfast and London, 30 November 2023 – Diaceutics, leaders in diagnostic commercialization, will join the ‘Best of British’ Conference organised by Stifel and the London Stock Exchange, taking place in New York City on 13 December 2023.
Belfast and London, 30 November 2023 – Diaceutics, leaders in diagnostic commercialization, will join the ‘Best of British’ Conference organised by Stifel and the London Stock Exchange, taking place in New York City on 13 December 2023.
Building on a series of successful engagements throughout the year, Diaceutics’ senior management will further engage with US investors on the unique positioning and opportunity of the company’s DXRX platform technology offering to the US Pharma marketplace, and its financial strength and growth.
Investors will have the chance to engage around the company’s strategic vision, ground-breaking technology advancements, superior return on investment metrics evidenced in pharmaceutical drug commercialization.
Ryan Keeling, CEO of Diaceutics who will be attending the event said:
“Attending the prestigious ‘Best of British’ conference, alongside other industry leaders provides us with the prime opportunity to showcase our compelling investment potential in the global pharmaceutical market where our technology shines brightest.”
The conference is a prime gateway for investors to explore the inherent value Diaceutics brings to pharmaceutical drug commercialization, both in terms of increased patient recruitment to drug, and reduced overhead spend on traditional and outdated commercialization strategies.
Furthermore, Diaceutics is set to shine a spotlight on the increased US investor interest in its ground-breaking digital offerings to the pharmaceutical sector, and attendees are invited to engage with company representatives where detailed discussions on investment opportunities, market trends and the future trajectory of precision medicine are encouraged.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.
For media enquiries
07540643725
